Cantor Fitzgerald Reiterates Neutral on Pacific Biosciences, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Ross Osborn has reiterated a Neutral rating on Pacific Biosciences (NASDAQ:PACB) and maintained a $14 price target.
September 26, 2023 | 3:49 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald analyst Ross Osborn has reiterated a Neutral rating on Pacific Biosciences and maintained a $14 price target.
The news is directly about Pacific Biosciences. The neutral rating and maintained price target suggest that the analyst sees no major changes in the company's outlook in the short term. This is likely to have a neutral impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100